|
|
 |
|
Viewing report
|
|
|
|
Immunotherapy in Oncology: Gaining Momentum
Bioseeker, Aug 2006, Pages: 228
The immunotherapy field in cancer has never been more potent than it is right now, including block buster drugs like Avastin, Erbitux, and Rituxan. Antibodies are making the headlines but cancer vaccines are not far away. The recent approval of Gardasil, a cervical cancer vaccine, will certainly become a strong representative of its kind. Future challenges for the industry lie in discovering strong antigens, effective immunomodulators and developing suitable delivery technologies.
Scope of this report
- In-depth competitive landscape assessment of the cancer immunotherapy market place; Including more than 200 immunotherapy drugs and pharmaceutical companies
- Thorough review of tumor antigen discovery, immunomodulating strategies and adjuvants
- Thorough review of antibody and vaccine delivery and technologies surrounding it - The next generation
- Progress analysis of six major cancer vaccine indications and late stage antibody development projects, including players, drugs, clinical progress and pitfalls
Research and analysis highlights
Among the targeted therapies for cancer, immunotherapy is probably the most versatile treatment strategy for the eradication of tumors, metastatic spread or not. Main strategies of cancer immunotherapy aim at exploiting the therapeutic potential of tumor-specific antibodies and cellular immune effector mechanisms (vaccines). Active immunotherapy, aiming at the generation of a tumor-specific immune response combining both humoral and cytotoxic T cell effector mechanisms by the host’s immune system, is advancing over passive antibody therapy, which relies on the repeated application of large quantities of tumor antigen-specific antibodies.
Key reasons to read this report
- Understand the clinical and strategic challenges to the commercialization of immunotherapy drugs
- Assess opportunities and risks for the continued development of both cancer antibodies and vaccines in different cancer indications.
- Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development
|
|
|
|
